Favrille Announces Results From Phase 3 Registration Trial

**Curis helping to treat cancer, neurological degenerative, kidney disorders, CUDC-101. Pathways, hedgehog, EGFR, Her2, Hsp90, Bcr-Abl/Src, CDK, BCL, MEK, VEGF, HDAC.**

Pathway 2 Curis Forum (Hedgehog and beyond) Forum Index » Clinical Trials News
Reply to topic
Favrille Announces Results From Phase 3 Registration Trial
RSS FEED


Joined: 05 Apr 2006
Posts: 19275
Post Posted: Wed May 28, 2008 9:58 pm Reply with quote
Favrille, Inc. (Nasdaq: FVRL) announced results from the Company's Phase 3 registration trial of Specifid(TM) following Rituxan(R) in patients with follicular B-cell non-Hodgkin's lymphoma (NHL).

Read more...
View user's profileSend private message
Favrille Announces Results From Phase 3 Registration Trial
All times are GMT - 7 Hours  
Page 1 of 1  
  
  
Pathway 2 Curis Forum (Hedgehog and beyond) Forum Index » Clinical Trials News
 Reply to topic  
Forum Map
Site Map